Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382(9):810–821

Article  CAS  PubMed  Google Scholar 

Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C et al (2022) Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med 387(3):217–226

Article  CAS  PubMed  Google Scholar 

Mayer EL, Ren Y, Wagle N, Mahtani R, Ma C, DeMichele A, et a (2023) Abstract GS3–06: GS3–06 Palbociclib after CDK4/6i and endocrine therapy (PACE): a randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2-metastatic breast cancer. Cancer Res 83(5_Supplement):GS3–06.

Cardoso F, McArthur HL, Schmid P, Cortés J, Harbeck N, Telli ML et al (2023) LBA21 KEYNOTE-756: phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer. Ann Oncol 34:S1260–S1261

Article  Google Scholar 

Sharpe AH, Pauken KE (2018) The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 18(3):153–167

Article  CAS  PubMed  Google Scholar 

Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16(9):563–580

Article  CAS  PubMed  Google Scholar 

Nunes Filho P, Albuquerque C, Pilon Capella M, Debiasi M (2023) Immune checkpoint inhibitors in breast cancer: a narrative review. Oncol Ther 11(2):171–183

Article  PubMed  PubMed Central  Google Scholar 

Hylton N (2006) MR Imaging for assessment of breast cancer response to neoadjuvant chemotherapy. Magn Reson Imaging Clin N Am 14(3):383–389

Article  PubMed  Google Scholar 

Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E (1999) Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol Off J Am Soc Clin Oncol 17(1):110–119

Article  CAS  Google Scholar 

Van Goethem M, Schelfout K, Dijckmans L, Van Der Auwera JC, Weyler J, Verslegers I et al (2004) MR mammography in the pre-operative staging of breast cancer in patients with dense breast tissue: comparison with mammography and ultrasound. Eur Radiol 14(5):809–816

Article  PubMed  Google Scholar 

Davis PL, Staiger MJ, Harris KB, Ganott MA, Klementaviciene J, McCarty KS et al (1996) Breast cancer measurements with magnetic resonance imaging, ultrasonography, and mammography. Breast Cancer Res Treat 37(1):1–9

Article  CAS  PubMed  Google Scholar 

Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM (2002) Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol 179(5):1193–1199

Article  PubMed  Google Scholar 

Fatayer H, Sharma N, Manuel D, Kim B, Keding A, Perren T et al (2016) Serial MRI scans help in assessing early response to neoadjuvant chemotherapy and tailoring breast cancer treatment. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol 42(7):965–972

CAS  Google Scholar 

Li H, Yao L, Jin P, Hu L, Li X, Guo T et al (2018) MRI and PET/CT for evaluation of the pathological response to neoadjuvant chemotherapy in breast cancer: A systematic review and meta-analysis. The Breast 1(40):106–115

Article  Google Scholar 

Yeh E, Slanetz P, Kopans DB, Rafferty E, Georgian-Smith D, Moy L et al (2005) Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol 184(3):868–877

Article  PubMed  Google Scholar 

Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS et al (2005) MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. Am J Roentgenol 184(6):1774–1781

Article  Google Scholar 

Musall BC, Abdelhafez AH, Adrada BE, Candelaria RP, Mohamed RMM, Boge M et al (2021) Functional tumor volume by fast dynamic contrast-enhanced MRI for predicting neoadjuvant systemic therapy response in triple-negative breast cancer. J Magn Reson Imaging 54(1):251–260

Article  PubMed  Google Scholar 

Hylton NM, Gatsonis CA, Rosen MA, Lehman CD, Newitt DC, Partridge SC et al (2016) Neoadjuvant chemotherapy for breast cancer: functional tumor volume by MR imaging predicts recurrence-free survival—results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. Radiology 279(1):44–55

Article  PubMed  Google Scholar 

Jafri NF, Newitt DC, Kornak J, Esserman LJ, Joe BN, Hylton NM (2014) Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy. J Magn Reson Imaging 40(2):476–482

Article  PubMed  Google Scholar 

QuantumLeap Healthcare Collaborative. I-SPY Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2) [Internet]. clinicaltrials.gov; 2023 Jul [cited 2023 Aug 9]. Report No.: NCT01042379. Available from: https://clinicaltrials.gov/study/NCT01042379

SD-101—Investigational Therapeutic Candidate [Internet]. 2022 [cited 2023 Aug 10]. Available from: https://trisaluslifesci.com/candidate-sd-101/

Melisi D, Frizziero M, Tamburrino A, Zanotto M, Carbone C, Piro G et al (2014) Toll-like receptor 9 agonists for cancer therapy. Biomedicines 2(3):211–228

Article  PubMed  PubMed Central  Google Scholar 

Humbert M, Guery L, Brighouse D, Lemeille S, Hugues S (2018) Intratumoral CpG-B promotes antitumoral neutrophil, cDC, and T-cell cooperation without reprograming tolerogenic pDC. Cancer Res 78(12):3280–3292

Article  CAS  PubMed  Google Scholar 

Frank MJ, Reagan PM, Bartlett NL, Gordon LI, Friedberg JW, Czerwinski DK et al (2018) In situ vaccination with a TLR9 agonist and local low-dose radiation induces systemic responses in untreated indolent lymphoma. Cancer Discov 8(10):1258–1269

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ribas A, Medina T, Kummar S, Amin A, Kalbasi A, Drabick JJ et al (2018) SD-101 in combination with pembrolizumab in advanced melanoma: results of a phase Ib. Multicenter Study Cancer Discov 8(10):1250–1257

Article  CAS  PubMed  Google Scholar 

Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33(31):3541–3543

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rugo Hope S, Olopade Olufunmilayo I, DeMichele A, Yau C, van ’t Veer Laura J, Buxton Meredith B et al (2016) Adaptive randomization of Veliparib–Carboplatin treatment in breast cancer. N Engl J Med 375(1):23–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park John W, Liu Minetta C, Yee D, Yau C, van ’t Veer Laura J, Symmans WF et al (2016) Adaptive randomization of Neratinib in early breast cancer. N Engl J Med 375(1):11–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol Off J Am Soc Clin Oncol 25(28):4414–4422

Article  Google Scholar 

Cardoso F, van’t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S et al (2016) 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 375(8):717–729.

Article  CAS  PubMed  Google Scholar 

Mittempergher L, Kuilman MM, Barcaru A, Nota B, Delahaye LJMJ, Audeh MW et al (2022) The ImPrint immune signature to identify patients with high-risk early breast cancer who may benefit from PD1 checkpoint inhibition in I-SPY2. J Clin Oncol 40(16_suppl):514–514.

Article  Google Scholar 

Brufsky AM, Kuilman M, Mukhtar R, Wolf DM, Yau C, O’Shaughnessy J et al (2023) Abstract PD9–08: ImPrint immune signature in 10,000 early-stage breast cancer patients from the real-world FLEX database. Cancer Res 83(5_Supplement):PD9–08.

Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O et al (2016) Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab. J Clin Oncol Off J Am Soc Clin Oncol 34(13):1510–1511.

Article  CAS  Google Scholar 

Di Giacomo AM, Danielli R, Guidoboni M, Calabrò L, Carlucci D, Miracco C et al (2009) Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother CII 58(8):1297–1306

Article  PubMed  Google Scholar 

Cascone T, Weissferdt A, Godoy MCB, William WN, Leung CH, Lin HY et al (2021) Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun 12(1):5045

Article  CAS